查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046217

寡核苷酸合成市場－全球產業規模、佔有率、趨勢、機會、預測：依產品類型、應用、最終用戶、地區、競爭格局分類，2021-2031年

Oligonucleotide Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球寡核苷酸合成市場預計將從 2025 年的 47.7 億美元大幅成長至 2031 年的 102.6 億美元，複合年成長率為 13.62%。

這一成長主要得益於化學合成特定核酸序列的技術發展，這些序列對於研究、分子診斷和治療方法創新至關重要。推動該市場發展的關鍵因素是核酸治療方法獲得監管部門核准的數量不斷增加，以及其在治療罕見遺傳疾病方面的應用日益廣泛。例如，美國基因與細胞治療學會 (ASGCT) 報告稱，2025 年第二季度共有 38 項新的 RNA 療法試驗，其中 74% 的試驗針對非腫瘤領域，這凸顯了除傳統癌症治療之外，合成寡核苷酸的強勁且多樣化的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 47.7億美元
市場規模：2031年 102.6億美元
複合年成長率：2026-2031年 13.62%
成長最快的細分市場 研究
最大的市場 北美洲

然而，阻礙市場廣泛成長的一大障礙在於如何有效地將藥物遞送至肝臟以外的其他器官。寡核苷酸固有的負電荷和體積限制了其生物利用度和細胞內吸收，因此需要複雜的遞送系統和化學修飾。然而，這些解決方案會增加研發成本，並為製藥公司帶來技術挑戰。

市場促進因素

全球寡核苷酸合成市場的主要驅動力是製藥和生物技術領域研發投入的不斷成長。隨著RNA療法臨床療效的不斷提升，領先企業正大力投資生產自主化和拓展其核苷酸藥物研發管線。這項投資對於解決複雜化學合成中固有的供應鏈瓶頸至關重要。例如，BioPharma Dive在2025年4月報道稱，諾華公司宣布將在五年內投資230億美元，以加強在美國的生產能力。這項投資尤其包括新建一座反義寡核苷酸藥物生產設施，顯示該產業正小規模研究生產轉向先進治療產品組合的商業化規模合成。

此外，寡核苷酸藥物核准數量的不斷增加凸顯了這些治療方法的安全性和有效性，進一步推動了市場成長。因此，市場對穩定、商業規模的合成過程的需求日益成長。隨著每一種新藥的核准，候選藥物便轉化為可上市產品，這使得可靠、高純度的生產過程至關重要。 2025年2月，寡核苷酸治療學會強調，FDA於2024年6月核准骨髓發育不良症候群治療藥物伊美替司他（Rytelo）上市，顯著加強了法規環境。此類突破性事件增強了市場信心，並促進了合作。例如，AReNA在2025年報道稱，禮來公司已與Crayon Bio達成一項潛在價值10億美元的合作協議，旨在利用人工智慧技術開發創新寡核苷酸療法。

市場挑戰

全球寡核苷酸合成市場擴張面臨的一大持續性主要障礙是如何有效地將寡核苷酸遞送至肝臟以外的其他組織。由於這些分子本身體積較大且帶負電荷，它們能夠穿過中樞神經系統、心臟和肌肉等器官的細胞膜，限制了其在特異性標靶以外的生物利用度。這種生物學限制迫使研發人員將資源投入到高成本且複雜的遞送技術中，導致非肝臟標靶治療的研發週期延長，且上市所需的資本投入顯著增加。

因此，商業領域仍然高度集中而非多元化，肝外藥物研發計畫的高失敗率限制了最終上市的有前景產品的數量。這種限制限制了潛在收入，迫使市場依賴極少數成功的治療方法。例如，再生醫學聯盟在2025年報告中指出，僅10種產品就能貢獻全球整體先進醫學領域75%的收入。這種驚人的價值集中清楚地表明，遞送方面的挑戰如何直接阻礙了市場將新研究成果轉化為廣泛商業性成長的潛力。

市場趨勢

基於酵素的DNA合成平台的商業化正成為一股重要趨勢，為解決傳統化學亞磷醯胺法的難題提供了新的方案。這種生物學方法能夠建構更長、更精確的序列，且不會產生有毒的副產物，為合成生物學和精準醫學開闢了新的途徑。該技術正迅速發展，使得以往難以合成的複雜基因結構得以生產。例如，2025年1月，DNA Script公司宣布推出一項新的酵素合成功能，旨在產生難以合成的序列，包括那些GC含量高、二級結構複雜的序列，這些序列以往難以用標準桌上型系統合成。

同時，治療性寡核苷酸結構的日益複雜導致了外包給合約契約製造組織（CMO）的顯著增加。由於製藥研發公司需要應對複雜的修飾和嚴格的cGMP標準，它們越來越依賴專業的CDMO（合約研發生產組織），而不是為每個專案建立內部生產設施。大型契約製造公司的財務表現也印證了這一趨勢。例如，根據Bachem公司於2025年7月發布的《2025年半年報》，該公司CMC開發部門的收入成長了近37%，達到1.237億瑞士法郎，這一成長直接歸功於對複雜和先進肽寡核苷酸開發的強勁且不斷成長的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球寡核苷酸合成市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（合成寡核苷酸產品、試劑、設備、服務）
    • 按應用領域（研究、治療、診斷）
    • 按最終用戶分類（學術研究機構、製藥和生物技術公司、醫院、診斷實驗室）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美寡核苷酸合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲寡核苷酸合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區閉塞合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲寡核苷酸合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲寡核苷酸合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球寡核苷酸合成市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • Merck KGaA
  • BIO-Synthesis Inc
  • Eurofins Scientific SE
  • Danaher Corporation
  • Ajinomoto Co. Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16306

The global oligonucleotide synthesis market is anticipated to expand significantly, rising from USD 4.77 billion in 2025 to USD 10.26 billion by 2031, at a compound annual growth rate of 13.62%. This growth is fueled by the chemical creation of specific nucleic acid sequences, which are vital for research, molecular diagnostics, and therapeutic innovations. A key impetus for this market is the growing number of regulatory approvals for nucleic acid-based therapies and their increasing use in treating uncommon genetic conditions. For instance, in Q2 2025, the American Society of Gene & Cell Therapy reported 38 new RNA therapy trials, with 74% focusing on non-oncology areas, highlighting a strong and diverse demand for synthetic oligonucleotides extending beyond conventional cancer treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.77 Billion
Market Size 2031USD 10.26 Billion
CAGR 2026-203113.62%
Fastest Growing SegmentResearch
Largest MarketNorth America

Nevertheless, a major obstacle hindering widespread market growth is the challenge of effective intracellular delivery to organs other than the liver. Oligonucleotides' intrinsic negative charge and size limit their bioavailability and cellular absorption, requiring advanced delivery systems or chemical alterations. These solutions, however, escalate development expenses and create technical difficulties for pharmaceutical companies.

Market Driver

A primary accelerator for the global oligonucleotide synthesis market is the increasing expenditure on research and development within the pharmaceutical and biotechnology sectors. As RNA therapeutics achieve greater clinical success, leading pharmaceutical companies are investing heavily to achieve manufacturing independence and broaden their nucleotide-based drug pipelines. This financial commitment is essential for resolving supply chain constraints inherent in intricate chemical synthesis. For example, BioPharma Dive reported in April 2025 that Novartis announced a five-year, $23 billion strategic investment to enhance its U.S. production capabilities, specifically including new antisense oligonucleotide drug manufacturing facilities, demonstrating the industry's shift from small-scale research production to commercial-volume synthesis for advanced therapeutic portfolios.

Moreover, the growing number of regulatory approvals for oligonucleotide-based drugs further stimulates market growth by confirming the safety and effectiveness of these treatments, which in turn demands consistent commercial synthesis volumes. Each new approval converts a developmental candidate into a market-ready product, requiring reliable, high-purity manufacturing. The Oligonucleotide Therapeutics Society highlighted in February 2025 that the FDA's June 2024 approval of Imetelstat (Rytelo) for myelodysplastic syndromes significantly bolstered the regulatory environment. Such milestones boost confidence and drive collaborations; for instance, AReNA reported in 2025 that Eli Lilly formed a partnership with Creyon Bio, potentially worth up to $1 billion, to utilize artificial intelligence in developing innovative oligonucleotide therapies.

Market Challenge

A significant and ongoing impediment to the expansion of the global oligonucleotide synthesis market is the challenge of achieving effective intracellular delivery to tissues beyond the liver. The inherent large size and negative charge of these molecular sequences impede their capacity to traverse cell membranes in organs like the central nervous system, heart, and muscle, resulting in limited bioavailability outside of liver-specific targets. This biological limitation compels developers to allocate resources towards costly and intricate delivery technologies, thereby extending development periods and considerably increasing the financial investment needed to introduce non-liver targeted therapeutics to the market.

As a result, the commercial sector remains highly concentrated rather than diversified, with high failure rates in extrahepatic drug programs limiting the number of viable products reaching the market. This limitation restricts potential revenue and maintains the market's reliance on a select few successful therapies. For instance, the Alliance for Regenerative Medicine reported in 2025 that a mere 10 products generated 75% of the global revenue in the advanced therapy sector. This pronounced concentration of value clearly illustrates how delivery challenges directly hinder the market's potential to transform new research into broad commercial growth.

Market Trends

The commercialization of enzymatic DNA synthesis platforms is becoming a significant trend, offering a solution to the constraints of conventional chemical phosphoramidite techniques. This biological method facilitates the creation of longer, more accurate sequences without generating toxic by-products, thus opening new avenues in synthetic biology and precision medicine. The technology is quickly evolving to manage increasingly complex genetic structures that were previously challenging to produce. For example, DNA Script announced in January 2025 the launch of a new enzymatic synthesis capability designed to produce difficult sequences, including those with high GC content and intricate secondary structures, which were problematic for standard benchtop systems.

Simultaneously, the market is observing a notable increase in outsourcing to Contract Manufacturing Organizations (CMOs), driven by the growing structural complexity of therapeutic oligonucleotides. As drug developers navigate elaborate modifications and strict cGMP standards, they are increasingly depending on specialized CDMOs instead of developing internal facilities for each project. This trend is supported by the financial results of key contract manufacturers. Bachem's 'Half-Year Report 2025' in July 2025, for instance, indicated a nearly 37% rise in revenue for its CMC Development division to CHF 123.7 million, directly attributing this growth to the strong and expanding demand for complex peptide and oligonucleotide development.

Key Market Players

  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • Merck KGaA
  • BIO-Synthesis Inc
  • Eurofins Scientific SE
  • Danaher Corporation
  • Ajinomoto Co. Inc.
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

Report Scope

In this report, the Global Oligonucleotide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oligonucleotide Synthesis Market, By Product Type

  • Synthesized Oligonucleotide Products
  • Reagents
  • Equipment
  • Services

Oligonucleotide Synthesis Market, By Application

  • Research
  • Therapeutics
  • Diagnostics

Oligonucleotide Synthesis Market, By End User

  • Academic Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Hospital
  • Diagnostic Laboratories

Oligonucleotide Synthesis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oligonucleotide Synthesis Market.

Available Customizations:

Global Oligonucleotide Synthesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oligonucleotide Synthesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Synthesized Oligonucleotide Products, Reagents, Equipment, Services)
    • 5.2.2. By Application (Research, Therapeutics, Diagnostics)
    • 5.2.3. By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Hospital, Diagnostic Laboratories)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Oligonucleotide Synthesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oligonucleotide Synthesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Oligonucleotide Synthesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Oligonucleotide Synthesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Oligonucleotide Synthesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oligonucleotide Synthesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Oligonucleotide Synthesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Oligonucleotide Synthesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Oligonucleotide Synthesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Oligonucleotide Synthesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Oligonucleotide Synthesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oligonucleotide Synthesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Oligonucleotide Synthesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Oligonucleotide Synthesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Oligonucleotide Synthesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Oligonucleotide Synthesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Oligonucleotide Synthesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oligonucleotide Synthesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Oligonucleotide Synthesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Oligonucleotide Synthesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Oligonucleotide Synthesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oligonucleotide Synthesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Oligonucleotide Synthesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Oligonucleotide Synthesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oligonucleotide Synthesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Merck KGaA
  • 15.4. BIO-Synthesis Inc
  • 15.5. Eurofins Scientific SE
  • 15.6. Danaher Corporation
  • 15.7. Ajinomoto Co. Inc.
  • 15.8. Biogen Inc.
  • 15.9. Ionis Pharmaceuticals, Inc.
  • 15.10. Sarepta Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer